ASH17

ASH 2017: What you missed
BioPharma Dive
Wed, 12/13/17 - 06:35 pm
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
Tue, 12/12/17 - 10:50 pm
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint
Fierce Biotech
Tue, 12/12/17 - 10:10 am
Roche
ASH17
clinical trials
non-Hodgkin's lymphoma
antibody-drug conjugate
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half
Fierce Pharma
Tue, 12/12/17 - 10:06 am
ASH17
JNJ
Darzalex
Multiple Myeloma
Janssen
ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts
Fierce Pharma
Mon, 12/11/17 - 11:35 am
ASH17
Seattle Genetics
Adcetris
Hodgkin's lymphoma
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
Motley Fool
Mon, 12/11/17 - 10:02 am
Bluebird Bio
bb2121
CAR-T
Celgene
Multiple Myeloma
ASH17
ASH17: Benefit of Gilead's CAR-T remains durable over longer term
BioPharma Dive
Sun, 12/10/17 - 11:27 pm
ASH17
Gilead Sciences
CAR-T
Yescarta
diffuse large B-cell lymphoma
#ASH17: Verastem’s AbbVie castoff is headed for the FDA — even after missing overall survival goal
Endpoints
Sun, 12/10/17 - 11:22 pm
ASH17
AbbVie
Verastem
FDA
duvelisib
chronic lymphocytic leukemia
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Endpoints
Sun, 12/10/17 - 11:10 am
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma
ASH17: Seattle Genetics sees market opportunity in cancer combo success
BioPharma Dive
Sun, 12/10/17 - 09:59 am
ASH17
Seattle Genetics
Adcetris
Hodgkin's lymphoma
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
Sat, 12/9/17 - 02:31 pm
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene